# Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

> **NCT06943586** · NA · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 200 (estimated)

## Conditions studied

- Stroke
- Transient Ischemic Attack (TIA)

## Interventions

- **GENETIC:** CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)

## Key facts

- **NCT ID:** NCT06943586
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-09
- **Primary completion:** 2028-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06943586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06943586, "Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06943586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*